OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
By C. Tournigand, A. Cervantes, A. Figer, G. Lledo, M. Flesch, M. Buyse, L. Mineur, E. Carola, P. Etienne, F. Rivera and 6 more. Journal of Clinical Oncology, 2006
721 citations recorded by the source corpus.
Subfields: Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/76b1d5a61ab008adfe0e04ad4c232b3a1a03e0dc
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016, methodology): “The OPTIMOX-1 trial randomised patients to receive FOLFOX4 until progression (or unacceptable toxicity) or FOLFOX7 (using a higher dose of oxaliplatin) for six cycles after which patients whose disease responded continued on maintenance 5-FU with the reintroduction of oxaliplatin only at disease pro”